Skip to main content
OpenTrials

Clinical trial condition

Relapsed/Refractory Multiple Myeloma

Explore clinical trials studying Relapsed/Refractory Multiple Myeloma. Study availability and eligibility vary by location and protocol.

51 public trials 22 recruiting studies
Refine in advanced search Browse all conditions

Relapsed/Refractory Multiple Myeloma trial results

Recruiting

A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

NCT06508983

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Beijing Chaoyang Hospital of Capital Medical University Beijing, Beijing Municipality, China
  • Guangzhou First People's Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • First Affiliated Hospital of Henan University of Science and Technology Luoyang, Henan, China
View Trial Details
Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Standford Cancer Institute Palo Alto, California, United States
  • Sylvester Cancer Center Miami, Florida, United States
  • Winship Cancer Institute Atlanta, Georgia, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
View all 32 locations
View Trial Details
Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

NCT05722418

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • CU Anschutz Medical Campus, Anshutz Cancer Pavillion Aurora, Colorado, United States
  • Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics Miami, Florida, United States
  • University of Kentucky/ Markey Cancer Center Lexington, Kentucky, United States
View all 16 locations
View Trial Details
Recruiting

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

NCT06668792

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • SBHI of the Kaliningrad region "Central City Clinical Hospital" Kaliningrad, Russia
  • SAHI "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigala" Kazan', Russia
  • FSBI of science "Kirov research Institute of Hematology and blood transfusion of the Federal medical and biological Agency" Kirov, Russia
  • Regional Government-Owned Publicly Funded Healthcare Institution "Regional Clinical Hospital" Krasnoyarsk, Russia
View all 20 locations
View Trial Details

Related conditions